Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of the American Academy of Dermatology

Topics

Physics

Quantum Mechanics

Medicine

Physiology

Dermatology

Show all topics

DOI

10.1016/j.jaad.2019.07.074

License

CC-BY-NC-ND

Other Formats

PDF